Halozyme Therapeutics, Inc.
HealthcareNASDAQ:HALO · NASDAQ Global Select
-$1.23 today
Vol 1.04M · Avg 1.63M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
649.2%
avg 152.5%
ROIC
23.6%
avg 5.1%
ROA
12.5%
avg 4.0%
Analysis
ROE is currently the strongest return metric at 649.2% versus its period average of 152.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Helen I. Torley | President, Chief Executive Officer & Director | $2.17M | — | 63 | $1,923.00 | <0.01% |
Mark Snyder | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | $1.03M | — | 59 | $14,022.00 | 0.01% |
Cortney Caudill | Senior Vice President & Chief Operating Officer | $952,725.00 | — | 49 | $0.00 | <0.01% |
David A. Ramsay | Interim Chief Financial Officer | $262,461.00 | — | 61 | $10,000.00 | <0.01% |
Charles Theuer | Chief Medical Officer | — | — | 62 | — | — |
Christopher Wahl | Chief Scientific Officer | — | — | — | — | — |
Chase Coffman | President of Hypercon | — | — | — | — | — |
Rhys de Callier | Chief Strategy Officer | — | — | — | — | — |
Tram Bui | Head of Investor Relations & Corporate Communications | — | — | — | — | — |
Paul Spence | Chief Commercial Officer | — | — | 57 | $6,040.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
70
$28.20M
Net Sentiment
$28.20M
Net selling
Most Active
Torley Helen
61 transactions
1–10 of 70
Analysis
Insiders reported 0 buys worth $0.00 and 70 sells worth $28.20M over the last 12 months. That adds up to net selling of $28.20M. Torley Helen was the most active insider with 61 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +47.2% | +18.8% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +47.2% over three years. Forward estimates point to Revenue at +18.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B
Henry Schein, Inc.
NASDAQ:HSIC
$9.26B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.90B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Merus N.V.
MRUS
$6.83B
Grifols, S.A.
NASDAQ:GRFS
$6.46B
Abivax S.A.
NASDAQ:ABVX
$6.33B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.08B
Who manages HALO?
Halozyme Therapeutics, Inc. (HALO) lists 10 active executives. The top listed executive is Charles Theuer, Chief Medical Officer.
Are HALO insiders buying or selling?
Recent insider activity shows net selling of $28.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.